JD Health Inks Multiple Cooperation Agreements with Global Pharmaceutical Companies

JD Health Inks Multiple Cooperation Agreements with Global Pharmaceutical Companies

by Vivian Yang

As a driving force in China’s “internet + healthcare” industry, JD Health reached a number of cooperation agreements with global pharmaceutical firms at the 3rd China International Import Expo (CIIE) held from Nov. 5-10 in Shanghai.

Enlin Jin, general manager of JD Health’s pharmaceutical department and head of strategy and investment, said at CIIE that as the global healthcare industry has seen explosive growth in 2020, China’s strong economic recovery and development in digitalization promises even greater space for the industry’s continued growth. JD Health will continue to give full play of its own capacities (and that of its ecosystem) to promote the development of integrated healthcare services both online and offline, joining hands with more and more partners to provide better healthcare products and services to the Chinese people, and support China’s healthcare industry to become more intelligent and digitalized.

JD Pharmacy, JD.com’s online pharmaceutical retail platform, has been the platform of choice for many global brands to launch new medicines online. During the CIIE, JD Health and Pfizer joined hands to launch STAQUIS (舒坦明), a crisaborole ointment for atopic dermatitis. STAQUIS is the first and only non-steroidal topical phosphodiesterase-4 (PDE-4) inhibitor approved on the Chinese market. Its debut on JD Pharmacy provides a trusted and convenient channel for many adults and children who are in need of this specific treatment.

JD Health and Pfizer’s signing ceremony at CIIE

STAQUIS

In the area of chronic disease management, JD Health and the American pharmaceutical company Bristol-Myers Squibb announced the co-establishment of a cloud platform for innovative treatment for liver diseases. The platform aims to provide high-quality medicines, professional healthcare services and education activities for over 300 million liver disease patients in China.

Enlin Jin(right) of JD Health and Siyuan Chen of Bristol-Myers Squibb at CIIE

Abbott and JD Health agreed to expand their cooperation in the areas of online medical centers for specific diseases, chronic disease management, patient’s recruitment, academic promotion and financing services.

JD Health and Abbot representatives on the cooperation signing ceremony on CIIE

A memorandum was signed between GlaxoSmithKline and JD Health to deepen collaboration on vaccinations. The two sides will explore new vaccination supply and service solutions based on the strength of the internet and other technologies to provide premier and safe vaccinations and make them accessible to a wider range of people in China. The first disease prevention effort between the two sides will be on the zonster vaccination.

JD Health and GSK on the MOU signing ceremony at CIIE

At the same time, JD Health also joined Sanofi and other platforms to co-create a cooperation mechanism to support patients of rare diseases on medical payments. Under this mechanism, patients are able to have easier access to medical treatment for their rare diseases and benefit from combined financial support from public welfare funds, social crowdfunding, commercial insurance and other medicine assistance sources.

JD Health joins the establishment ceremony of the payment cooperation mechanism for patients of rare diseases

JD Health is China’s largest online healthcare platform and online pharmacy. Through its fast development on omnichannel, the company has demonstrated strong performance in the Chinese market in the supply of new medicines, cross-border healthcare products, critical medical equipment, injection products, cold-chain products, medicine for rare diseases and more.

 

(vivian.yang@jd.com)

  • Recent posts

  • Topics

  • Trusted by Top Global Brands

    Discover JD.com brand partners